$
16.360
-0.62(-3.651%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
16.600
Open
16.580
VWAP
16.46
Vol
213.38K
Mkt Cap
20.94B
Low
16.260
Amount
3.51M
EV/EBITDA(TTM)
--
Total Shares
114.12M
EV
2.21B
EV/OCF(TTM)
--
P/S(TTM)
330.33
Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. It has established commercial partnerships in Europe and China for certain Phase III assets.
Show More
1 Analyst Rating
up Image
83.37% Upside
Wall Street analysts forecast MESO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MESO is 30.00 USD with a low forecast of 30.00 USD and a high forecast of 30.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
up Image
83.37% Upside
Current: 16.360
sliders
Low
30.00
Averages
30.00
High
30.00
Jefferies
David Stanton
Buy
to
Hold
downgrade
2025-07-18
Reason
Jefferies analyst David Stanton downgraded Mesoblast to Hold from Buy with a price target of A$2.60, up from A$2.50, following the fiscal Q4 report. The firm estimates 68 paid infusions were given during the quarter of Ryoncil in the U.S. with six patents likely having completed treatment. Jefferies updated fiscal 2025 estimates and awaits the company's annual results in August.
Piper Sandler
Edward Tenthoff
Buy
Reiterates
$15 → $24
2025-02-07
Reason
Jefferies
David Stanton
Strong Buy
to
Hold
Downgrades
n/a
2024-12-23
Reason
Jefferies downgraded Mesoblast to Hold from Buy with a price target of A$2.30, up from A$1.10. The firm updated the company's for the FDA'ss recent approval of Ryoncil in pediatric steroids-refractory acute graft-versus-host disease patients. While the market size is only 375 pediatric patients per year in the U.S., expansion of this indication is possible in adults if the upcoming adult trial is positive, the analyst tells investors in a research note. Jefferies continues to assume full U.S. reimbursement approval at the start of fiscal 2026. However, after Mesoblast's recent share price appreciation, the firm downgraded the shares on valuation.
Piper Sandler
Edward Tenthoff
Buy
Maintains
$11 → $15
2024-12-19
Reason
Maxim Group
Jason McCarthy
Hold
to
Strong Buy
Upgrades
$12
2024-09-24
Reason
Maxim upgraded Mesoblast to Buy from Hold with a $12 price target.
Cantor Fitzgerald
Louise Chen
Buy
Reiterates
n/a
2024-08-29
Reason

Valuation Metrics

The current forward P/E ratio for Mesoblast Ltd (MESO.O) is -29.13, compared to its 5-year average forward P/E of -10.84. For a more detailed relative valuation and DCF analysis to assess Mesoblast Ltd 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-10.84
Current PE
-29.13
Overvalued PE
-2.28
Undervalued PE
-19.41

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-20.93
Current EV/EBITDA
-60.46
Overvalued EV/EBITDA
6.15
Undervalued EV/EBITDA
-48.01

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
30.73
Current PS
42.86
Overvalued PS
48.80
Undervalued PS
12.66

Financials

Annual
Quarterly

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

MESO News & Events

Events Timeline

2025-07-17 (ET)
2025-07-17
20:41:12
Mesoblast reports Q1 Ryoncil gross revenue $13.2M
select
2025-06-12 (ET)
2025-06-12
05:18:33
Mesoblast gives update on Revascor accelerated approval, Ryoncil label extension
select
2025-05-15 (ET)
2025-05-15
05:38:10
Mesoblast gets years of orphan-drug exclusive approval from FDA for Ryoncil
select
Sign Up For More Events

News

2.0
07-19NASDAQ.COM
Mesoblast Breaks Above 200-Day Moving Average - Bullish for MESO
9.5
07-18Benzinga
Independent Bank Posts Upbeat Earnings, Joins Blaize Holdings, Interactive Brokers Group And Other Big Stocks Moving Higher On Friday
4.0
07-18Benzinga
This Elevance Health Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Sign Up For More News

FAQ

arrow icon

What is Mesoblast Ltd (MESO) stock price today?

The current price of MESO is 16.36 USD — it has decreased -3.65 % in the last trading day.

arrow icon

What is Mesoblast Ltd (MESO)'s business?

arrow icon

What is the price predicton of MESO Stock?

arrow icon

What is Mesoblast Ltd (MESO)'s revenue for the last quarter?

arrow icon

What is Mesoblast Ltd (MESO)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Mesoblast Ltd (MESO)'s fundamentals?

arrow icon

How many employees does Mesoblast Ltd (MESO). have?

arrow icon

What is Mesoblast Ltd (MESO) market cap?